Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
90 hedge funds and large institutions have $93.6M invested in Y-mAbs Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 32 reducing their positions, and 29 closing their positions.
9.96% less ownership
Funds ownership: 53.89% → 43.93% (-10%)
10% less funds holding
Funds holding: 100 → 90 (-10)
22% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 32
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
72% less capital invested
Capital invested by funds: $340M → $93.6M (-$246M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.03M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.32M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.49M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.27M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.9M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.4M |
YMAB Hedge Fund Activity: Q4 2022 in Review
90 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2022, worth a combined $93.6M — down 72% from $340M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of YMAB and 20 opened new positions — a net loss of 9 holders — while 32 trimmed existing stakes and 25 added.
The largest buyer was Millennium Management, adding an estimated $8.03M. The largest seller was Wellington Management Group, exiting entirely with an estimated $28.1M sold.
- 90 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2022, down from 100 in Q3 2022.
- Funds reported $93.6M of Y-mAbs Therapeutics stock for Q4 2022, down 72% quarter-over-quarter.
- 20 funds opened new Y-mAbs Therapeutics positions in Q4 2022 and 29 closed out, a net change of -9 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $8.03M added.
- The largest Y-mAbs Therapeutics seller in Q4 2022 was Wellington Management Group, an estimated $28.1M sold.
Based on aggregated 13F filings for Q4 2022.